90
Participants
Start Date
March 1, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
June 30, 2026
LP-300
LP-300: 18.4 g/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.
Pemetrexed
Pemetrexed: 500 mg/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. After completion of the 4 to 6 cycles, patients will have the option to continue pemetrexed maintenance therapy until disease progression, unacceptable toxicity, or patient preference/physician discretion. The number of treatment cycles will be determined by PI discretion.
Carboplatin
Carboplatin: area under the concentration-time curve 5 mg/mL per minute (AUC5) by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.
RECRUITING
Fox Chase Cancer Center, Philadelphia
RECRUITING
Inova Fairfax Hospital, Fairfax
RECRUITING
UT Southwestern Medical Center, Dallas
RECRUITING
Precision NextGen Oncology and Research Center, Beverly Hills
RECRUITING
Cancer and Blood Specialists Clinic, Los Alamitos
RECRUITING
Los Angeles Cancer Network, Fountain Valley
RECRUITING
Hokkaido Cancer Center, Sapporo
RECRUITING
Kanagawa Cancer Center Hospital, Yokohama
RECRUITING
Tohoku University Hospital, Sendai
RECRUITING
Okayama University Hospital, Okayama
RECRUITING
National Cancer Center Hospital, Chuo-ku
RECRUITING
Chi Mei Medical Center, Tainan City
RECRUITING
National Cheng Kung University Hospital, Tainan City
RECRUITING
Taipei Veterans General Hospital, Taipei
RECRUITING
TriService General Hospital-Neihu Main Facility, Taipei
RECRUITING
National Taiwan University Hospital Hsin-Chu Branch, Taoyuan District
Lead Sponsor
Lantern Pharma Inc.
INDUSTRY